269 related articles for article (PubMed ID: 26639943)
1. Sodium-glucose cotransporter 2 inhibitor luseogliflozin improves glycaemic control, assessed by continuous glucose monitoring, even on a low-carbohydrate diet.
Nishimura R; Omiya H; Sugio K; Ubukata M; Sakai S; Samukawa Y
Diabetes Obes Metab; 2016 Jul; 18(7):702-6. PubMed ID: 26639943
[TBL] [Abstract][Full Text] [Related]
2. Sodium-glucose co-transporter-2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes: A randomized, open-label, 3-arm parallel comparative, exploratory study.
Yabe D; Iwasaki M; Kuwata H; Haraguchi T; Hamamoto Y; Kurose T; Sumita K; Yamazato H; Kanada S; Seino Y
Diabetes Obes Metab; 2017 May; 19(5):739-743. PubMed ID: 27990776
[TBL] [Abstract][Full Text] [Related]
3. Impact of Reduced Renal Function on the Glucose-Lowering Effects of Luseogliflozin, a Selective SGLT2 Inhibitor, Assessed by Continuous Glucose Monitoring in Japanese Patients with Type 2 Diabetes Mellitus.
Jinnouchi H; Nozaki K; Watase H; Omiya H; Sakai S; Samukawa Y
Adv Ther; 2016 Mar; 33(3):460-79. PubMed ID: 26846284
[TBL] [Abstract][Full Text] [Related]
4. Effects of luseogliflozin, a sodium-glucose co-transporter 2 inhibitor, on 24-h glucose variability assessed by continuous glucose monitoring in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, crossover study.
Nishimura R; Osonoi T; Kanada S; Jinnouchi H; Sugio K; Omiya H; Ubukata M; Sakai S; Samukawa Y
Diabetes Obes Metab; 2015 Aug; 17(8):800-4. PubMed ID: 25930989
[TBL] [Abstract][Full Text] [Related]
5. Substantial Effects of Luseogliflozin Revealed by Analyzing Responses to Postprandial Hyperglycemia: Post Hoc Subanalyses of a Randomized Controlled Study.
Samukawa Y; Omiya H; Watase H; Nozaki K; Sakai S; Nishimura R
Adv Ther; 2016 Jul; 33(7):1215-30. PubMed ID: 27255763
[TBL] [Abstract][Full Text] [Related]
6. Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study.
Seino Y; Sasaki T; Fukatsu A; Ubukata M; Sakai S; Samukawa Y
Curr Med Res Opin; 2014 Jul; 30(7):1231-44. PubMed ID: 24673496
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of luseogliflozin added to insulin therapy in Japanese patients with type 2 diabetes: a multicenter, 52-week, clinical study with a 16-week, double-blind period and a 36-week, open-label period.
Seino Y; Sasaki T; Fukatsu A; Imazeki H; Ochiai H; Sakai S
Curr Med Res Opin; 2018 Jun; 34(6):981-994. PubMed ID: 29448833
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study.
Seino Y; Sasaki T; Fukatsu A; Sakai S; Samukawa Y
Curr Med Res Opin; 2014 Jul; 30(7):1219-30. PubMed ID: 24597840
[TBL] [Abstract][Full Text] [Related]
9. Sodium-glucose cotransporter-2 inhibitor luseogliflozin added to glucagon-like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: A 52-week, open-label, single-arm study.
Seino Y; Yabe D; Sasaki T; Fukatsu A; Imazeki H; Ochiai H; Sakai S
J Diabetes Investig; 2018 Mar; 9(2):332-340. PubMed ID: 28502112
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study.
Seino Y; Sasaki T; Fukatsu A; Ubukata M; Sakai S; Samukawa Y
Curr Med Res Opin; 2014 Jul; 30(7):1245-55. PubMed ID: 24708292
[TBL] [Abstract][Full Text] [Related]
11. Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus.
Haneda M; Seino Y; Inagaki N; Kaku K; Sasaki T; Fukatsu A; Kakiuchi H; Sato Y; Sakai S; Samukawa Y
Clin Ther; 2016 Jan; 38(1):66-88.e20. PubMed ID: 26718606
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, Pharmacodynamics, and Safety of Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Single-blind, Placebo-controlled Trial.
Sasaki T; Seino Y; Fukatsu A; Ubukata M; Sakai S; Samukawa Y
Adv Ther; 2015 Apr; 32(4):319-40. PubMed ID: 25855342
[TBL] [Abstract][Full Text] [Related]
13. The effect of luseogliflozin on bone microarchitecture in older patients with type 2 diabetes: study protocol for a randomized controlled pilot trial using second-generation, high-resolution, peripheral quantitative computed tomography (HR-pQCT).
Haraguchi A; Shigeno R; Horie I; Morimoto S; Ito A; Chiba K; Kawazoe Y; Tashiro S; Miyamoto J; Sato S; Yamamoto H; Osaki M; Kawakami A; Abiru N
Trials; 2020 May; 21(1):379. PubMed ID: 32370806
[TBL] [Abstract][Full Text] [Related]
14. Sodium glucose co-transporter 2 inhibitor luseogliflozin in the management of type 2 diabetes: a drug safety evaluation.
Yabe D; Hamamoto Y; Seino Y; Kuwata H; Kurose T; Seino Y
Expert Opin Drug Saf; 2017 Oct; 16(10):1211-1218. PubMed ID: 28741382
[TBL] [Abstract][Full Text] [Related]
15. Factors Influencing Change in Serum Uric Acid After Administration of the Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin in Patients With Type 2 Diabetes Mellitus.
Chino Y; Kuwabara M; Hisatome I
J Clin Pharmacol; 2022 Mar; 62(3):366-375. PubMed ID: 34545949
[TBL] [Abstract][Full Text] [Related]
16. Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling of Luseogliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, in Japanese Patients with Type 2 Diabetes Mellitus.
Samukawa Y; Mutoh M; Chen S; Mizui N
Biol Pharm Bull; 2017; 40(8):1207-1218. PubMed ID: 28769002
[TBL] [Abstract][Full Text] [Related]
17. Fifty-two-week long-term clinical study of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.
Seino Y; Kaku K; Inagaki N; Haneda M; Sasaki T; Fukatsu A; Ubukata M; Sakai S; Samukawa Y
Endocr J; 2015; 62(7):593-603. PubMed ID: 25971406
[TBL] [Abstract][Full Text] [Related]
18. Luseogliflozin: first global approval.
Markham A; Elkinson S
Drugs; 2014 Jun; 74(8):945-50. PubMed ID: 24848756
[TBL] [Abstract][Full Text] [Related]
19. Safety, pharmacokinetics, and pharmacodynamics of single and multiple luseogliflozin dosing in healthy Japanese males: a randomized, single-blind, placebo-controlled trial.
Sasaki T; Seino Y; Fukatsu A; Sakai S; Samukawa Y
Adv Ther; 2014 Mar; 31(3):345-61. PubMed ID: 24535625
[TBL] [Abstract][Full Text] [Related]
20. Gut Microbiota Changes by an SGLT2 Inhibitor, Luseogliflozin, Alters Metabolites Compared with Those in a Low Carbohydrate Diet in db/db Mice.
Hata S; Okamura T; Kobayashi A; Bamba R; Miyoshi T; Nakajima H; Kitagawa N; Hashimoto Y; Majima S; Senmaru T; Okada H; Ushigome E; Nakanishi N; Takakuwa H; Sasano R; Hamaguchi M; Fukui M
Nutrients; 2022 Aug; 14(17):. PubMed ID: 36079789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
